Amgen and Pfizer-backed oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.

US-based cancer immunotherapy developer NexImmune filed for an $86.3m initial public offering on the Nasdaq Global Market on Tuesday that would give pharmaceutical firms Pfizer and Amgen the chance to exit. NexImmune is working on immunotherapies based on a nanotechnology platform developed at Johns Hopkins University that are intended to leverage nanoparticles that function as…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.